Gaithersburg, Maryland-based Sirnaomics Inc., a developer of RNAi therapeutics, has raised $105 million in Series D financing. The investors included Rotating Boulder Fund, Walvax Biotechnology Co Ltd, Sunshine Riverhead Capital, Sangel Capital, Longmen Capital, HongTao Capital and Alpha Win Capital. Chinese Renaissance and Huatai Financial Holdings served as financial advisors on the transaction.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: